Research | Volume 38, Article 355, 13 Apr 2021 | 10.11604/pamj.2021.38.355.20386

Seroprevalence of hepatitis B and associated factors among inmates: a cross sectional study in the Douala New Bell Prison, Cameroon

Mathurin Pierre Kowo, Firmin Ankouane Andoulo, Daniel Tchamdeu Sizimboue, Antonin Wilson Ndjitoyap Ndam, Larry Tangie Ngek, Charles Kouanfack, Hubert Leundji, Rocard Djanteng, Bruno Ela Ondo, Judith Ndongo Torimiro, Elie-Claude Ndjitoyap Ndam, Oudou Njoya

Corresponding author: Mathurin Pierre Kowo, Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon

Received: 17 Sep 2019 - Accepted: 08 May 2020 - Published: 13 Apr 2021

Domain: Hepatology

Keywords: Prevalence, risks factors, hepatitis B, prison, Cameroon

©Mathurin Pierre Kowo et al. Pan African Medical Journal (ISSN: 1937-8688). This is an Open Access article distributed under the terms of the Creative Commons Attribution International 4.0 License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cite this article: Mathurin Pierre Kowo et al. Seroprevalence of hepatitis B and associated factors among inmates: a cross sectional study in the Douala New Bell Prison, Cameroon. Pan African Medical Journal. 2021;38:355. [doi: 10.11604/pamj.2021.38.355.20386]

Available online at: https://www.panafrican-med-journal.com/content/article/38/355/full

Home | Volume 38 | Article number 355

Research

Seroprevalence of hepatitis B and associated factors among inmates: a cross sectional study in the Douala New Bell Prison, Cameroon

Seroprevalence of hepatitis B and associated factors among inmates: a cross sectional study in the Douala New Bell Prison, Cameroon

Mathurin Pierre Kowo1,&, Firmin Ankouane Andoulo1, Daniel Tchamdeu Sizimboue2, Antonin Wilson Ndjitoyap Ndam1, Larry Tangie Ngek1, Charles Kouanfack3, Hubert Leundji4, Rocard Djanteng5, Bruno Ela Ondo2, Judith Ndongo Torimiro1, Elie-Claude Ndjitoyap Ndam1, Oudou Njoya1

 

1Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon, 2Université des Montagnes, Bangangté, Cameroon, 3Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, Dschang, Cameroon, 4Centre Médical de L'Estuaire Douala, Douala, Cameroon, 5Medical Center, New Bell Prison, Douala, Cameroon

 

 

&Corresponding author
Mathurin Pierre Kowo, Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon

 

 

Abstract

Introduction: in Cameroon, data on viral hepatitis B infection in prison environments is limited. We determined the prevalence of hepatitis B infection (HBV) and correlates among prisoners incarcerated at the Douala New Bell Central Prison in Cameroon.

 

Methods: this was a cross-sectional study carried out in July 2018 and included 940 randomly selected prisoners. Data were collected using pre-tested questionnaire while blood screening for HBV surface antigen (HBs Ag) used rapid test, with confirmation via Elisa test. Sociodemographic characteristics and risk factors were compared among the three age groups with respect to the prison's partitioning. Factors associated with positive HBs Ag were identified using logistic regression adjusted to age and gender. Confounders were then excluded by logistic multivariate analysis. All p values less than 0.05 were considered statistically significant.

 

Results: of the 940 prisoners selected, 94% were male. The mean age of the study population was 33.81 ± 10.35 years. The median duration of incarceration and median number of incarcerations were 12 months (IQR:5-36) and 1 (IQR:1-2) respectively. HBV prevalence was 12.9% (95% CI: 10.7-15%). The use of non-injectable illicit drugs (OR:3.5; 95% CI:1.9-6.2; P<0.001), sharing of needle or razors (aOR:24.1; 95% CI: 12.9-45.0; P<0.001), sharing of tooth brushes(aOR:2.7; 95% CI:0.9-7.4) (P=0.053), having tattoos or piercings (aOR:1.9; 95% CI:1.1-3.1; P=0.01) were significantly associated with HBs Ag seropositivity.

 

Conclusion: prisoners in this setting had a high prevalence of HBV and related risk factors. These findings highlight an urgent need to implement control strategies and programs that reach people in detention centers in Cameroon.

 

 

Introduction    Down

Hepatitis B virus (HBV) infection is a major global public health problem, with significant mortality and morbidity especially in sub-Saharan African and East Asian countries [1]. Globally, in 2015, 257 million people were living with chronic HBV infection according to the World Health Organization (WHO) estimates [1]. The African and Western Pacific regions accounted for 68% of those infected. The number of HBV related deaths is about 650,000 every year mainly due to liver cirrhosis and/or hepatocellular carcinoma (HCC) [2].

 

A recently publish systematic review and meta-analysis on seroprevalence of hepatitis B virus infection in Cameroon has estimated the overall pooled prevalence of HBs Ag at 11.2%, making Cameroon one of the most affected countries in the world [3]. Prisoners are a high-risk population for infectious diseases with a high prevalence for viral hepatitis and HIV compared to the general population [4]. The overall prevalence of HBs Ag ranges from 0.3% to 25.5% has been reported by several studies in Europe [5], North America [6], Latin America [7] and Africa [8,9] among adult inmates. This high risk is linked to the prison setting with poor hygiene, promiscuity, malnutrition, tattooing and other forms of skin piercing, physical and moral violence, intravenous drug use, males having sex with males and lack of knowledge about HBV transmission modes [10,11].

 

In addition, prisoners suffered from limited access to appropriate health care services, lack of early detection and treatment of some chronic diseases and could serve as reservoirs for HBV infection. Despite the high prevalence of HBV infection in Cameroon, published data on the burden in prison settings are lacking. The aim of this study was to determine the prevalence of hepatitis B surface antigen and correlates among inmates of the Douala New Bell central prison in Cameroon.

 

 

Methods Up    Down

Study design: this was a cross sectional study conducted from November 2017 to October 2018 at the Douala New Bell Central Prison. It included 940 inmates randomly selected from a total of 3356 inmates, using systematic random sampling. This was based on the alphabetical list of prisoners present at the start of the study, applying a sampling interval of 4. Data collected included age, gender, profession before detention, level of education, marital status, religion, number and duration of incarcerations. Data on risk factors for HBV transmission were also collected on a pretested questionnaire. Rapid detection of HBsAg was done using an immunochromatography assay (HEPATM (HBs Ag) strip test) (RECKON DIAGNOSTICS P.LTD) (3/7, BIDC, Gorwa Vadogara 390 016 (INDIA)) in accordance with the manufacturer´s instruction. This rapid test is used for qualitative detection of HBs Ag in serum and plasma. Inmates tested positive on the rapid test had a confirmatory Elisa test.

 

Study setting: the New Bell Central Prison is located in the New-Bell suburb of Douala (Cameroon). It was created in 1930 and is the main prison for the Littoral Region of Cameroon. It constitutes with the Kondengui Central Prison Yaoundé the 2 main central prisons in Cameroon. It is a mixed prison with separate male, female and children quarters. It has a capacity of 960 places for over 3500 prisoners with 27 cells containing between 30-200 prisoners per cell giving an average space of 0.2m2 per inmate for a minimum standard of 4m2. The New Bell Central Prison is divided into 10 quarters for 4 different groups of persons: minors (males below 18), the elderly (males above 55), females of all age groups and males between 18 and 55. Males between 18 and 55 constitute 86.7% of all inmates. The prison offers health services for inmates and has one medical doctor, two senior nurses, five assistant nurses and two laboratory technicians. All new prisoners have complete physical examination by the site physician with systematic human immunodeficiency virus (HIV) screening but no screening for viral hepatitis.

 

Data analysis: data were analyzed using the Statistical Package for Social Sciences (SPSS) version 21.0 (Institute, Cary, NC, USA). The results were expressed in numbers and percentages for qualitative variables, mean ± SD for normally distributed variables, median with interquartile range (IQR) for non-normally distributed variables. Sociodemographic and risk factors were described and compared across three age groups with respect to the prison´s partitioning (children below 18, adults between 18 and 55 and the elderly above 55) using the Chi-square test. Factors associated to positive HBs Antigen were identified using logistic regression adjusted to age and gender. The odds ratio (95% CI) were calculated to assess the strength of association. Confounders were then excluded by logistic multivariate analysis including age, gender and all significant variables. P values less than 0.05 were considered statistically significant.

 

Ethical considerations: ethical clearance was obtained from the institutional ethical review board of the Université des Montagnes-Bangangté, Cameroon, while administrative authorization was obtained from the Regional Delegate for Penitentiary Administration for the Littoral Region and the Superintendent in charge of the New Bell Central Prison. Prison inmates who tested positive for HBs antigen were referred to the medical doctor in charge of the prison health service for proper management. All included inmates signed a written consent form.

 

 

Results Up    Down

Of the 940 prisoners included, 94% (884) were males and 6% (56) were females. The mean age was 33.81 years ± 10.35 years with extremes of 14 and 74 years. The most represented age group was 30-39 years. The median duration of incarceration and median number of incarcerations were 12 months (IQR:5-36) and 1 (IQR:1-2) respectively (Table 1). The prevalence of HBs Ag was 12.9% (95% CI:10.7-15%) and did not significantly differ among age groups (p=0.86) (Table 2). Among 940 prisoners, 60% (566) had never heard of viral hepatitis before this study. The vaccination coverage rate for HBV was 4.3% (n=40) (Table 3).

 

Out of the 940 inmates, 66.9% (629) had no formal education and had no formal education and this was not associated with HBs Ag positivity (aOR:0.9; 95% CI: 0.5-1.7; P=0.859). No association was found between HBs Ag positivity and gender (aOR:1.7; 95% CI: 0.7-4.5; P=0.246) although they were more HBs Ag positivity in female (Table 4). The use of non-injectable illicit drugs (OR:3.5; 95% CI:1.9-6.2; P<0.001), sharing of needle or razors (aOR:24.1; 95% CI:12.9-45.0; P<0.001), sharing of tooth brushes (aOR:2.7; 95% CI:0.9-7.4) (P=0.053), having tattoos or piercings (aOR:1.9; 95% CI:1.1-3.1; P=0.01) were significantly associated with HBs antigen seropositivity (Table 5).

 

 

Discussion Up    Down

Overcrowding in prisons remains a major problem in both developed and developing countries and is a key factor for a myriad of other problems which ultimately turn these custodial settings into fertile breeding grounds for infectious diseases such as viral hepatitis, HIV, syphilis, gonorrhea and tuberculosis [4,8]. Knowledge of the prevalence of HBV infection and associated factors in prisoners is therefore an important step for the planning and implementation of preventive measures in this population. This study aimed to determine the prevalence of HBV infection and correlates among prison inmates in Cameroon and addressed issues for preventive measures in this setting. The prevalence of chronic HBV infection in our study population was 12.9%. This prevalence is higher than that of the general population in Cameroon recently estimated at 7.1% (95% CI: 2.6-13.5%) [3]. Our result confirms the high endemicity of HBV infection in Cameroon involving both the general population and special population such as individuals who are detained.

 

Similar high prevalences of HBV infection in prisoners, higher than that of general population from which they arise have been reported among inmates in many other parts of the World [4,8,9,12-14]. In high endemicity area like sub-Saharan Africa and East Asian Countries, high prevalence of the HBV infection has mainly been attributed to HBV transmission occurring predominantly early in the life either through mother to child transmission and horizontal transmission, low HBV vaccine coverage, unsafe medical and traditional procedures [15,16]. The high prevalence of HBV in prisoners in Cameroon found in this study suggests the presence of some additional risk factors that could explained the spread of this infection in prisons.

 

In the present study, the use of non-injectable illicit drugs but not injectable illicit drugs was associated to HBV infection. This finding is however, paradoxical as several authors have reported an association between the use of injectable illicit drugs and HBV infection [17,18]. This finding could be attributed to the following reasons: an underestimation of the use of injectable illicit drugs by inmates because of oral interview as a means of data collection, difficulties in acquiring injectable materials in the prison setting and the absence of complete physical examination to assess for injection site. Sharing of needles and razors, past medical history of tattooing/piercings were also significantly associated to HBV infection. HBV is a highly infectious agent which can remain stable on environmental surfaces for 7 days [19] and practices such as sharing of needles and razors, tattoos or piercing and scarifications found respectively in 28.8%, 38.3%; 41.6% of our study population may have played a role in the diffusion of the virus in this population. However, whether these practices are more frequent in the Cameroonian prisoners than the general population is still unknown.

 

We also demonstrated that the anti-HBV vaccination coverage rate was low at 4.3%. The low anti-HBV vaccination rate in this high-risk population could be explained by the absence of policy of screening and vaccination of these high-risk individuals in Cameroon. In effect, safe and effective vaccines against hepatitis B have been available since 1982. This vaccine has been shown to be effective in 95% of cases in preventing individuals from developing chronic infections and in reducing the incidence of related complications [20]. Since 1990, the WHO recommends introduction of HBV vaccine into the expanded program of immunization in member states [21]. Unfortunately, in Cameroon, this vaccine was only introduced in the year 2005 as an integral part of the routine expanded program of immunization at 6, 10 and 14 weeks after delivery. If this measure represents an important step to control HBV infection in Cameroon, it fails to protect the adult populations especially those at risk of HBV infection as there is no HBV catch-up vaccination policy for this population.

 

The low vaccination coverage rate found in detainees in Cameroon is consistent with that reported in another risk population by Desmond Aroke et al. who reported vaccination coverage rate of only 16.8% among Cameroonian medical students [22]. These results emphasize the urgent need to implement systematic screening and catch-up vaccination policies in risk populations for HBV infection in Cameroon. Low level of education was not associated with HBV transmission. The link between the level of education and the risk of transmission of HBV is still a matter of controversy. Some studies [23,24] have demonstrated a clear link between low education and HBV infection and others did not [5]. To the best of our knowledge, this study is the first addressing the issue of HBV infection among prison inmates in Cameroon. This study was also done in one of the major central prisons in Cameroon accommodating more than three thousand inmates. The high prevalence of HBV infection reported in this study and the associated factors highlight the necessity of implementing preventive measures dedicated to this population. However, due to the unicentric nature of this study these findings should be interpreted with caution. Further studies involving multiple prison centers is encouraged.

 

 

Conclusion Up    Down

Inmates in New Bell Central Prison accumulate risk factors for viral hepatitis thus contributing to the high prevalence in this setting. There is therefore an urgent need to implement a viable health policy to control HBV infection in this population.

What is known about this topic

  • Viral hepatitis is common in the prison setting;
  • Multiple risk factors for HBV transmission exists in the prison setting;
  • Publish data in Cameroon is rare.

What this study adds

  • It gives HBV prevalence and risk factors in the prison setting in Cameroon;
  • Emphasizes the importance of a structured health policy for systematic screening for viral hepatitis and vaccination for negative inmates.

 

 

Competing interests Up    Down

The authors declare no competing interests.

 

 

Authors' contributions Up    Down

All the authors have read and agreed to the final manuscript.

 

 

Tables Up    Down

Table 1: socio-demographic and carceral characteristics

Table 2: prevalence of HBs Antigen positivity

Table 3: risk factors for HBV

Table 4: odd ratio for HBs Ag positivity according to socio-demographic and carceral characteristics among New Bell prison inmates in Douala

Table 5: odd ratio for HBs Ag positivity according to risk factors among New Bell prison inmates in Douala

 

 

References Up    Down

  1. World Health Organization. Global hepatitis report, 2017. 2017. Google Scholar

  2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2095-128. PubMed | Google Scholar

  3. Bigna JJ, Amougou MA, Asangbeh SL, Kenne AM, Noumegni SRN, Ngo-Malabo ET et al. Seroprevalence of hepatitis B virus infection in Cameroon: a systematic review and meta-analysis. BMJ Open. 2017;7(6):e015298. PubMed | Google Scholar

  4. Dolan K, Wirtz AL, Moazen B, Ndeffo-Mbah M, Galvani A, Kinner SA et al. Global burden of HIV, viral hepatitis and tuberculosis in prisoners and detainees. Lancet. 2016;388(10049):1089-1102. PubMed | Google Scholar

  5. Gétaz L, Casillas A, Siegrist CA, Chappuis F, Togni G, Tran NT et al. Hepatitis B prevalence, risk factors, infection awareness and disease knowledge among inmates: a cross-sectional study in Switzerland's largest pre-trial prison. J Glob Health. 2018;8(2):020407. PubMed | Google Scholar

  6. Hennessey KA, Kim AA, Griffin V, Collins NT, Weinbaum CM, Sabin K. Prevalence of infection with hepatitis B and C viruses and co-infection with HIV in three jails: a case for viral hepatitis prevention in jails in the United States. J Urban Health. 2009 Jan;86(1):93-105. PubMed | Google Scholar

  7. Barros LA, Pessoni GC, Teles SA, Souza SM, Matos MA, Martins RM et al. Epidemiology of the viral hepatitis B and C in female prisoners of Metropolitan Regional Prison Complex in the State of Goiás, Central Brazil. Rev Soc Bras Med Trop. 2013 Jan-Feb;46(1):24-9. PubMed | Google Scholar

  8. Adjei AA, Armah HB, Gbagbo F, Ampofo WK, Quaye IKE, Hesse IFA et al. Prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus and syphilis among prison inmates and officers at Nsawam and Accra, Ghana. J Med Microbiol. 2006;55(Pt 5):593-597. PubMed | Google Scholar

  9. Adoga MP, Banwat EB, Forbi JC, Nimzing L, Pam CR, Gyar SD et al. Human immunonodeficiency virus, hepatitis B virus and hepatitis C virus: seroprevalence, co-infection and risk factors among prison inmates in Nasarawa State, Nigeria. J Infect Dev Ctries. 2009;3(7):539-547. PubMed | Google Scholar

  10. Tran NT, Dubost C, Baggio S, Gétaz L, Wolff H. Safer tattooing interventions in prisons: a systematic review and call to action. BMC Public Health. 2018;18;1015. PubMed | Google Scholar

  11. Falla AM, Hofstraat SHI, Duffell E, Hahné SJM, Tavoschi L, Veldhuijzen IK. Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups. BMC Infect Dis. 2018;18(1):79. PubMed | Google Scholar

  12. Jaquet A, Wandeler G, Tine J, Dagnra CA, Attia A, Patassi A et al. HIV infection, viral hepatitis and liver fibrosis among prison inmates in West Africa. BMC Infect Dis. 2016;16;249. PubMed | Google Scholar

  13. Stasi C, Silvestri C, Fanti E, Fiandra TD, Voller F. Prevalence and features of chronic viral hepatitis and HIV coinfection in Italian prisons. Eur J Intern Med. 2016;34:e21-e22. PubMed | Google Scholar

  14. Reekie JM, Levy MH, Richards AH, Wake CJ, Siddall DA, Beasley HM et al. Trends in HIV, hepatitis B and hepatitis C prevalence among Australian prisoners - 2004, 2007, 2010. Med J Aust. 2014;200(5):277-80. PubMed | Google Scholar

  15. Breakwell L, Tevi-Benissan C, Childs L, Mihigo R, Tohme R. The status of hepatitis B control in the African region. Pan African Medical Journal. 2017;27(Suppl 3):17. PubMed | Google Scholar

  16. Ork V, Woodring J, Shafiqul Hossain M, Wasley A, Nagashima S, Yamamoto C et al. Hepatitis B surface antigen seroprevalence among pre- and post-vaccine cohorts in Cambodia, 2017. Vaccine. 2019;37(35):5059-5066. PubMed | Google Scholar

  17. Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):e1192-e1207. PubMed | Google Scholar

  18. Adjei AA, Armah HB, Gbagbo F, Ampofo WK, Boamah I, Adu-Gyamfi C et al. Correlates of HIV, HBV, HCV and syphilis infections among prison inmates and officers in Ghana: a national multicenter study. BMC Infect Dis. 2008;8:33. PubMed | Google Scholar

  19. Lira R, Maldonado-Rodriguez A, Rojas-Montes O, Ruiz-Tachiquin M, Torres-Ibarra R, Cano-Dominguez C et al. Use of dried blood samples for monitoring hepatitis B virus infection. Virol J. 2009;6:153. PubMed | Google Scholar

  20. Chiang CJ, Yang YW, You SL, Lai MS, Chen CJ. Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. JAMA. 2013;310(9):974-6. PubMed | Google Scholar

  21. Kane MA. Global status of hepatitis B immunisation. Lancet. 1996;348(9029):696. PubMed | Google Scholar

  22. Aroke D, Kadia BM, Anutebeh EN, Belanquale CA, Misori GM, Awa A et al. Awareness and vaccine coverage of hepatitis B among Cameroonian medical students. Biomed Res Int. 2018 Sep 25;2018:3673289. PubMed | Google Scholar

  23. Pereira LM, Martelli CM, Merchn-Hamann E, Montarroyos UR, Braga MC, de Lima ML et al. Population-based multicentric survey of hepatitis B infection and risk factor differences among three regions in Brazil. Am J Trop Med Hyg. 2009 Aug;81(2):240-7. PubMed | Google Scholar

  24. Vahid T, Kafaei J, Kabir A, Yektaparast B, Alavian SM. Hepatitis B prevalence and risk factors in blood donors in Ghazvin, Iran. Hakim Res J. 2005;5(4):117-122. Google Scholar

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research

Seroprevalence of hepatitis B and associated factors among inmates: a cross sectional study in the Douala New Bell Prison, Cameroon

Research

Seroprevalence of hepatitis B and associated factors among inmates: a cross sectional study in the Douala New Bell Prison, Cameroon

Research

Seroprevalence of hepatitis B and associated factors among inmates: a cross sectional study in the Douala New Bell Prison, Cameroon

Volume 39 (May - Aug 2021)
This article authors
On Pubmed
On Google Scholar
Citation [Download]
Zotero
EndNote XML
Reference Manager
BibTex
ProCite

Navigate this article
Key words

Prevalence

Risks factors

Hepatitis B

Prison

Cameroon

Article metrics
Countries of access